Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies Launches CE-IVD Marked QuantStudio™ Dx Real-Time PCR Instrument in Europe

Published: Monday, November 19, 2012
Last Updated: Monday, November 19, 2012
Bookmark and Share
Flagship qPCR instrument offers reliability, accuracy, ease of use and flexibility for IVD and lab-developed diagnostic tests.

Life Technologies Corporation today announced the launch of its Applied Biosystems QuantStudio™ Dx Real-Time PCR Instrument designed to meet the specific needs of clinical diagnostic laboratories. The instrument is CE-IVD marked for use in Europe and represents a significant extension of Life Technologies' product offerings in the diagnostics arena.

"Molecular diagnostic tests based on real-time PCR have become indispensable to the clinical lab," said Ronnie Andrews, president of Medical Sciences at Life Technologies. "Molecular testing is the fastest-growing segment of the diagnostics market, and the QuantStudio™ Dx instrument has unique features that will allow us to capture that market growth."

The global IVD (in vitro diagnostic) market is approximately $52 billion and is expected to reach $70 billion by 2015. The current European IVD market is approximately $14 billion and expected to reach $17 billion by 2015.

The QuantStudio™ Dx Real-Time PCR Instrument can perform numerous diagnostic functions, including pathogen detection, gene expression analysis, SNP genotyping, copy number analysis, mutation detection, micro-RNA and other non-coding RNA analysis, and high-resolution melt analysis.

The instrument's touchscreen, reagent and sample tracking, and LIMS (Laboratory Information Management Systems) interface are specifically designed for ease of use. Flexibility is enabled through easily interchangeable thermal cycling blocks that accommodate 96- or 384-well plates and a proprietary qPCR microfluidics card, which can perform 48 tests on eight samples simultaneously without the need for liquid-handling robots. The card can also be used to design and implement custom tests. Life Technologies is currently developing diagnostic tests utilizing this format.

Two software options are available on the instrument. The QuantStudio™ Dx Software runs IVD (in vitro diagnostic) tests in a secure mode with pre-set run and analysis parameters, while the QuantStudio™ Test Development Software enables development of custom tests and supports clinical research projects.

"We recognize that clinical laboratories have multiple needs," said Andrews. "Accuracy and reliability are paramount when running diagnostic tests for physician reporting. In addition medical research labs need instrumentation that supports experimental work. The QuantStudio™ Dx instrument addresses both these needs."

The instrument is being released with CE-marked Quidel® Molecular Assay for C. difficile for detection of hospital-acquired infections, which Life Technologies distributes. Additional Quidel Molecular infectious disease applications are currently under development and will be available in 2013, including an influenza A + B Assay, a human metapneuomvirus (hMPV) + respiratory syncytial virus (RSV) Assay, and a herpes simplex virus 1 and 2, and varicella zoster virus (chicken pox and shingles) Assay.

Life Technologies plans to submit the QuantStudio™ Dx Real-Time PCR Instrument for 510(k) clearance to the United States Federal Food and Drug Administration (FDA) in December 2012.

The QuantStudio™ Dx Real-Time PCR Instrument is among a growing line of Life Technologies platforms for diagnostic use. The Applied Biosystems 3500 Dx Genetic Analyzer, a Sanger sequencing instrument, is currently CE-IVD marked. The company also offers the AcroMetrix® line of quality controls for molecular diagnostic assays.

"The Life Technologies Applied Biosystems brand has a 30-year heritage of leadership in the PCR market," said Andrews. "We also have a broad partnership base in the diagnostic and pharmaceutical space that will support content development across our Sanger and next generation sequencing instruments - platforms that we expect will play an increasingly important role in the clinic. In short, Life Technologies has the capability and the commitment to fully equip the diagnostic lab of the future."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Acquisition Approved by Life Technologies Stockholders
Company announced that its stockholders voted to adopt the previously announced merger agreement.
Thursday, August 22, 2013
Life Technologies to Collaborate with Merck Serono
Long-term collaboration is aimed at developing, obtaining regulatory approval and commercializing companion diagnostics for selected Merck Serono drug development programs.
Wednesday, July 17, 2013
Life Technologies Screening Technology Receives Emergency Use Authorization
Life Technologies supports global effort to help accelerate emergency screening of Novel Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Wednesday, June 26, 2013
Life Technologies Acquires KDR Biotech
The acquisition is part of Life Technologies strategic international growth plan in fast-growing markets.
Friday, April 12, 2013
Life Technologies to Invest $18 Million in Facility Expansion and Current GMP Compliance Plan
Project aims to broaden product offerings to growing diagnostics and pharmaceutical customer base.
Tuesday, April 02, 2013
Life Technologies Announces Fourth Quarter and Fiscal 2012 Results
Fourth quarter revenue increased 3% to $999 million, or 4.5% excluding currency.
Tuesday, February 12, 2013
Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Products
Life's Applied Biosystems Dx Genetic Analyzer and SeCore® kits constitute first sequence-based system cleared for HLA typing.
Tuesday, February 12, 2013
JAMA Study Demonstrates Efficacy of Life Technologies' Lung Cancer Test
Genetic test identifies patients at high risk for mortality in the earliest stage of lung cancer. Study suggests test could maximize the benefits of early screening if used in combination with computed tomography.
Thursday, November 08, 2012
Life Technologies Announces Third Quarter 2012 Results
Revenue for the third quarter was $911 million, a decrease of 1.9 percent over the $929 million reported for the third quarter of 2011. Excluding the impact of currency, revenue growth for the quarter was 1.4 percent compared to the same period of the prior year.
Monday, November 05, 2012
VelaDx Signs Agreement with Life Technologies to Develop IVD Tests on Ion PGM Sequencer
Semiconductor sequencing brings unprecedented power to diagnostic tests to transform personalized medicine.
Wednesday, October 10, 2012
Life Technologies Acquires Compendia Bioscience
Bioinformatics expertise will enable deeper engagement with established customer base of leading pharmaceutical companies.
Tuesday, October 09, 2012
Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing
Life and Southern African Treatment and Resistance Network (SATuRN) partner in sequencing-based surveillance of drug resistance,in order to increases access in Africa.
Tuesday, July 24, 2012
Acquisition of Navigenics Expands Life Technologies' Capabilities
Addition of Navigenics' physician portal provides informatics to support patient management.
Thursday, July 19, 2012
Acquisition of Navigenics Expands Life Technologies' Capabilities in Diagnostics
CLIA-certified laboratory enables life technologies to launch lab-developed tests and expand partnership program in companion diagnostics.
Wednesday, July 18, 2012
Life Technologies to Accelerate Development of Ion Torrent Semiconductor Technology
Company to accelerate technology for a broad set of proteomic and antibody-based applications after passing internal Life Technologies R&D milestones.
Thursday, July 12, 2012
Scientific News
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!